-
BESINS Healthcare
- Chief Business Officer
2018 - maintenant
BESINS Healthcare ("BESINS''; www.besins-healthcare.com) is a well-established, independent family-owned and Monaco-headquartered global pharmaceutical company (900+ headcounts including 500+ sales force) that sells 30+ women's and men's health products in 90+ countries worldwide, directly via 20+ fully owned subsidiaries [USA, EU (France, Germany, England, Ireland, Belgium, Netherlands & Nordics), CIS, Russia, Greater China, SEA-ASPAC (Indonesia, Philippines, Thailand & Vietnam), LATAM (Brazil, Colombia & Mexico)] or indirectly via 80+ partners (e.g. Abbott, AbbVie, Merck, Novo Nordisk, etc.). BESINS, a world leader and a pioneer in hormone-based transdermal gels, has developed several natural hormone-based therapies in gynecology (e.g. Utrogestan®, Œstrogel®) and andrology (e.g. AndroGel®). It has grown steadily over the years and has now sale revenues around 250m EUR .
* Organize the Business Development department and implement process (across all 20+ BESINS' subsidiaries) for finding, evaluating, structuring and negotiating partnerships.
* Led the finding and evaluation of 550+ external growth opportunities (including M&A, in-licensing of new women's or men's health products and geographical expansion for BESINS' products).
* Led the in-licensing of late stage/revenues-generating products (12 deals signed and several term sheets at advance stage of negotiation).
* Led the out-licensing of Œstrogel® (after retrieving the rights back from Shiseido) and another product (confidential) to Fuji Pharma in Japan and of Utrogestan® to Valeo Pharma in Canada.
* Generate potentially about 450m EUR sale revenues over the next five years.
-
AVADEL Pharmaceuticals
- Vice-President, Alliance Management & Licensing
2010 - 2017
AVADEL Pharmaceuticals (NASDAQ: AVDL; past FLAMEL Technologies) went through, successfully, various transformational changes since the acquisition of ÉCLAT Pharmaceuticals ("ÉCLAT'') in Mar. 2012, shifting from a standalone fee-for-services drug delivery business towards being a profitable specialty pharma developing differentiated pharmaceutical products by utilizing its proprietary Drug Delivery Platforms ("DDPs'') and in- licensing/acquiring new products. On Jan. 2017, FLAMEL became AVADEL Pharmaceuticals (www.avadel.com). AVADEL, headquartered in Dublin, Ireland with operations in St. Louis, USA, is an emerging biopharmaceutical company focusing on the development and potential FDA approval of FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness ("EDS'') and cataplexy. In addition, AVADEL develops and markets in the USA a portfolio of
FDA-approved sterile injectable drugs used in the hospital setting.
* Actively involved in several transformational deals (due diligences and negotiations) pertaining to the out- licensing of LiquiTime® US OTC products to Elan/Perrigo (Oct. 2015), the out-licensing of Micropump®, LiquiTime™ and Medusa™ to Recipharm (Jul. 2015), the sale of FLAMEL's CDMO business, including the assignation of GlaxoSmithKline's supply agreement (Coreg CR®) to Recipharm (Dec. 2014), the sale of FLAMEL's Micropump® aspirin product (Durlaza®) to New Haven Pharmaceuticals (Dec. 2012) and the acquisition of ÉCLAT (Mar. 2012) incl. Bloxiverz®, Vazculep®, and Akovaz™.
* Actively involved in in-licensing or acquisition pertaining to late stage products (confidential).
* Responsible for the out-licensing of Medusa™ DDP and Exenatide (type II diabetes) product; prepared confidential information package, built data room, outreach over 80 prospects, led due diligences, identified and contracted w. investment broker.
* Responsible for managing and expanding strategic alliances with GlaxoSmithKline (Coreg CR®; license agreement, and manufacturing and supply agreement), Perrigo (LiquiTime® US OTC products) and Recipharm (CDMO; $3.5-4.0m annual budget over 5 years).
* Responsible for managing and leading assignments and/or terminations of several partnerships with Acorda Therapeutics, AstraZeneca, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, Corning, Endo Pharmaceuticals, Janssen (J&J), Merck Serono, Regeneron, Roche, Servier and Pfizer/Wyeth.
* Support CEO with annual reports and strategic plans drafting, presentations to the Board of Directors and participations, as senior management, to staff representative bodies' regular meetings.
* Led optimization of Company real estate properties (down sized to 3 buildings from 4).
-
Amgen
- Director, Business Development
PARIS
2007 - 2010
Responsible for organizing and leading all due diligences pertaining to BiTE® antibody's intellectual
property,businessandlegalaspects,out-licensingSingleChainAntibody'spatentportfolio,in-licensing
new BiTE® antibody targets, searching new mode of administration/formulation technology platforms
for BiTE® antibody, establishing partnerships with CDMOs for antibody manufacturing.
Key Contributions: Over 15 deals sourced in, negotiated and signed (new BiTE® antibody targets in-
licensing; SR formulation; Single Chain Antibody's patent portfolio research
licenses with Pfizer and Takeda; manufacturing, tech transfer and commercial
supply agreement with Lonza for Blincyto® (MT103; blinatumomab), Bayer
Schering and Boehringer Ingelheim). Participated to negotiation of ``BiTE®
antibody platform'' deals with Bayer Schering, Sanofi Aventis (deal sourced-in;
over ~ EUR 500m deal value excl. royalties) and Boehringer Ingelheim.
-
APTANOMICS
- CEO, Board of Directors Member and Liquidator
2007 - 2009
APTANOMICS, a privately held and Venture Capitalists ("VCs'')-funded biopharmaceutical company, developed peptides for drug discovery or as biological therapeutics using its proprietary peptide aptamer technology from the Massachusetts General Hospital and Harvard Medical School. Its product development pipeline included Bcl antagonist and a kinase antagonist in the field of oncology. The Company pursued additional drug discovery and development programs in partnerships with leading pharmaceutical companies, including with Boehringer and Wyeth/Pfizer (undisclosed).
* Responsible for the financial recovery and liquidation of the Company on the behalf of majority shareholders, a VCs syndicate composed of AGF Private Equity, BioAm, CDC Innovation and Ventech.
* Negotiated successfully multiple settlements, i.e. employees and past CEO dismissals/mutual separation agreements, legal redress intended by minority shareholders (scientific founders), and debt payments claimed by several suppliers.
* Sold all APTANOMICS' remaining assets to several third parties, including IMAXIO.
* Successfully solved all outstanding remaining issues and obtained positive cash flow, including liquidation bonus, at business termination.
-
Consultant (Self-employed)
- CONSULTANT
2006 - 2007
- VIROPRO International (Montréal, Canada) * Participated for the negotiation of a development and manufacturing agreement with Intas (India). * Participated for the negotiation of a collaboration agreement with Biochallenge (Tunisia).
- CRUCELL (now Johnson & Johnson; Leiden, The Netherlands) * Responsible for prospecting the French market, identified and participated to the out-licensing of PER.C6® technology to LFB Biotechnologies (Jul. 2007).
-
SHIGAMEDIX
- Founding CEO
2005 - 2006
SHIGAMEDIX, privately held, was the first biopharmaceutical company issued from the research valorization policy of The Curie Institute. The Company was granted a worldwide exclusive license on a patent portfolio owned by The Curie Institute, INSERM, CNRS and Paris VI University. SHIGAMEDIX used protein vector derived from the Shigella bacterium (STxB technology which elicits cytotoxic CD8 T lymphocytes and antibody responses), for developing therapeutic vaccines for the treatment of cancers and infectious diseases. The Company's lead vaccine targeted HPV (Human Papilloma Virus), causing cervical cancer. SHIGAMEDIX had partnerships with a number of pharmaceutical and biotechnology companies, including GSK Biologicals and Avesthagen.
* Responsible for setting-up SHIGAMEDIX, including writing the business plan, implementing the shareholders' agreement, conducting road shows with VCs and raising seed-funding ( EUR 0.5m).
* Led the in-licensing of 4 patent families from Curie Institute/CNRS/Inserm/Paris VI.
* Led the negotiation and closing of a development and license option agreement with GSK Biologicals.
* Led the negotiation and closing of co-development (costs, risks and profit sharing) agreement with Avesthagen.
-
BIONEST Partners
- Senior Consultant
2003 - 2005
BIONEST Partners is a global consulting firm focused on pharma, biotech, medical device and diagnostics that helps clients navigate complex product development issues in order to drive growth, create value and gain competitive advantage. The Company also offer our expertise and analytic skills to support investors with due diligence assignments in these markets (www.bionest.com).
* Responsible for consulting mission for various clients across multiple drugs, therapeutic areas, technology platforms and territories, e.g.: - Business development activities for Active Biotech's products pipeline targeting neurodegenerative diseases, autoimmunity and cancers, for certain of Innate Pharma's monoclonal antibodies, for Ipsogen's oncogenomic diagnostic products, for FLAMEL [deal with GSK (Coreg CR®), and sourced- in and initiated discussions with BMS (Medusa™-insulin) and TAP (Micropump®-lanzoprazole)] and for Neurochem's Alzheimer drug; and, - Proposed and implemented industrial solutions for the divestment/restructuring of Aventis' Romainville site, including the setting-up of OroXcell spin-off; and,- Proposed strategy for spin-offing certain of Ethypharm's drug delivery platforms, as part of Ethypharm's Angers site divestment/restructuring; and, - Proposed growth strategy to Stallergènes and Prostrakan.
-
AVIDIS (now IMAXIO/OSIVAX)
- Founding CEO
2000 - 2002
“Leaving the Bench to Become an Entrepreneur” http://www.sciencemag.org/ careers/2000/07/business-plans-leaving-bench-become-entrepreneur.
AVIDIS, a spin-off of the Medical Research Council (“MRC”) and the University of Cambridge (United-Kingdom), was formed to create immune-therapeutics through its unique protein engineering technology platform, Heptafold® (an oligomerization system to improve the immune response on otherwise poorly immunogenic antigens) and its OverExpress® bacterial expression system of otherwise insoluble recombinant proteins. IMAXIO is now an integrated biotechnology company focused on immunology (www.imaxio.com). It owns a pipeline of vaccines composed of a marketed vaccine against human leptospirosis commercialized in France (Spirolept®), and clinical-stage and preclinical-stage products for infectious diseases (malaria, influenza, etc.) and oncology, based on its IMX313 and IMX313P technology platforms (derivatives of Heptafold®). In 2015, IMAXIO reached €2m in sales of immuno‐therapeutics.
* Responsible for setting-up AVIDIS, including writing the business plan, implementing the shareholders’ agreement, conducting road shows with VCs and raising seed-funding (€3m).
* Led the in-licensing of 10 patent families from the MRC and the University of Cambridge, including patents from Sir John E. WALKER (Nobel Prize in Chemistry in 1997; covering OverExpress®) and from Sir Alan R. FERSHT.
* Responsible for building-up and managing 15 headcounts team.
* Led the out-licensing of OverExpress® to leading pharmaceutical companies (confidential).
* Responsible for the re-orientation of the Company’s business strategy towards immunology.
-
Medical Research Council, CNRS, ESBS
- SCIENTIFIC RESEARCHER
1992 - 2000
* Post-doctoral research with Sir Alan R. FERSHT and Sir Greg P. WINTER at the Center for Protein Engineering of the MRC (Cambridge, United Kingdom). - 3 patent applications, 14 peer-reviewed scientific publications.
* Binational Ph.D. in Biochemistry, Molecular Biology, Protein Engineering from the universities of Strasbourg, France and Montréal, Canada. 1 patent application, 7 peer-reviewed scientific publications.
